Observational Registry Study of Quality of Life When Treating BTcP With Abstral

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This Observational Registry study is designed to collect self-reported Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program-enrolled patient experience with breakthrough cancer pain (BTcP) as a result of treatment with Abstral® through the use of Quality of Life and pain measurement tools administered via questionnaire.
Epistemonikos ID: 9e22d127841cf97ae2c12f3d8bb1d23828bfc18c
First added on: May 11, 2024